News | October 12, 2009

White House Honors PET Researcher with National Medal of Science

Joanna Fowler, Ph.D., receives the National Medal of Science.

October 12, 20009 - Joanna Fowler, Ph.D., a major contributor to brain research and a pioneer in molecular imaging, is being recognized by the White House with the National Medal of Science—the highest award for lifetime achievement in science. Eight other researchers will join Fowler to receive the award at a White House ceremony on October 7.

"SNM commends Joanna Fowler for her outstanding contributions to science," said Michael Graham, M.D., Ph.D., president of SNM. "Her advanced knowledge makes her stand out as one of the nation's foremost thought-leaders in nuclear medicine and molecular imaging, as well as a luminary in the quest to deliver the best patient care through the application of innovative research."

Currently serving as a senior chemist and director of the radiotracer chemistry, instrumentation and biological imaging program at the U.S. Department of Energy's Brookhaven National Laboratory in Upton, N.Y., Fowler has a long career filled with many illustrious achievements in research. Her work using the molecular imaging technique, positron emission tomography (PET) imaging, has led to significant advances in the study of how drugs, disease and aging affect the brain.

Fowler has also been instrumental in laying the groundwork for how disease is diagnosed today. In 1976, she and her colleagues synthesized 18F-fluorodeoxyglucose (FDG), a radiotracer used in PET that is widely relied on today to diagnose cancer and study brain and heart abnormalities.

Fowler's research interests are focused on how addictions cause changes to circuits in the brain. By measuring the uptake and movement of cocaine and methamphetamine in the brain, Fowler's studies have shed new light on the addictive power of drugs. She has also researched the use of PET to track the action of therapeutic drugs and explore the introduction of new drugs into the practice of medicine. Additionally, Fowler has conducted studies on how variations in a certain gene may affect personality and vulnerability to psychiatric disorders. A chief discovery from this study is that cigarette smokers have reduced levels of monoamine oxidase (MAO)—an enzyme that breaks down dopamine—the neurotransmitter that mediates reward, motivation and movement. Her work in this area could have implications for the high rate of smoking in people who suffer from depression or addiction to drugs.

Fowler has published about 350 peer-reviewed articles and holds eight patents for radiolabeling procedures. Her recognition for the distinguished National Science Award follows several other honors that she has received through the past several years, including SNM's Paul C. Aebersold Award for outstanding achievement in basic science applied to nuclear medicine, which she won in 1997.

Fowler earned a bachelor's degree in chemistry from the University of South Florida in 1964 and a doctorate in chemistry from the University of Colorado in 1967. She then went on to conduct postdoctoral research at the University of East Anglia in Norwich, England. She joined Brookhaven Laboratory in 1969 and has been conducting research there since that time.

The National Medal of Science was created in 1959 and is administered by the National Science Foundation. The award is given annually to individuals who have made outstanding contributions to science and engineering. Nominees are selected by a committee of Presidential appointees. Nominees are selected based on advanced knowledge and contributions to the biological, behavioral/social and physical sciences, as well as chemistry, engineering, computing and mathematics.

For more information: www.snm.org

Related Content

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
News | PET-CT | June 12, 2017
Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow...
Overlay Init